Skip to main content
SpringerLink
Log in

Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study

  • Special Article
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

This paper reviews the scientific and ethical issues surrounding the conduct of bridging studies in patients with Alzheimer's disease (AD). Bridging studies, so called because they facilitate the transition from phase I to phase II development, are late phase I safety/tolerance studies which determine the maximum tolerated dose (MTD) in patients before initiating phase II efficacy studies. Determining the MTD in patients is important because we have found that AD patients appear to respond to cholinergic compounds differently from normal volunteers, reaching a different MTD. Preliminary evidence of dose-related efficacy with two cholinergic compounds lends support to our contention that determination of the highest tolerated dose maximizes the potential to detect efficacy.

We will review the early clinical development of several cholinergic compounds and make recommendations for the design and conduct of bridging studies based on our experience. A fixed-dose panel design with dosages based on the MTD determined in normal volunteers is recommended. In order to minimize risk to the patients, ensuring that scientific benefits outweigh the risks, a bridging study must be supported by detailed preclinical toxicology, by a clinical research unit that is prepared to handle unexpected contingencies, and by the oversight of a competent, multi-disciplinary review board. Patients should be in good physical health (excluding AD), and a comprehensive informed consent procedure must be instituted. Carefully planned and well run bridging studies represent a scientifically and ethically sound approach to drug development in the Alzheimer's population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Weissman L (1981) Multiple-dose phase I trials-normal volunteers or patients? One viewpoint. J Clin Pharmacol 21:385–387

    Google Scholar 

  2. Oates JA (1972) A scientific rationale for choosing patients rather than normal subjects for phase I studies. Clin Pharmacol Ther 13:808–811

    Google Scholar 

  3. Lipsett MB (1982) On the nature and ethics of phase I clinical trials of cancer chemotherapies. JAMA 248:941–942

    Google Scholar 

  4. Gelijns AC (1990) Modern methods of clinical investigation. National Academy Press, Washington, DC

    Google Scholar 

  5. Owen F, Cross AF, Crow TJ, et al (1978) Increased dopamine receptor sensitivity in schizophrenia. Lancet ii:223–226

    Google Scholar 

  6. Weinberger DR (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44:660–669

    Google Scholar 

  7. Joyce JN, Shane A, Lexow N, et al (1993) Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacol 8:315–336

    Google Scholar 

  8. Laruelle M, Abi-Dargham A, Casanova MF, et al (1993) Selective abnormalities of prefrontal serotonergic receptors in schizophrenia:a postmortem study. Arch Gen Psychiatry 50:810–818

    Google Scholar 

  9. Sramek JJ, Simpson GM (1994) Pharmacodynamics of antipsychotic drugs in schizophrenia. In: Cutler NR, Sramek JJ, Narang PK (eds) Pharmacodynamics and drug development: perspectives in clinical pharmacology. Wiley, Sussex, pp 181–199

    Google Scholar 

  10. Grof P, Akhter MI, Campbell M, et al (1993) Clinical evaluation of psychotropic drugs for psychiatric disorders. Hogrefe and Huber, Berne, Switzerland, p 152

    Google Scholar 

  11. Wu JC, Buchsbaum MS, Hershey TG, et al (1991) PET in generalized anxiety disorder. Biol Psychiatry 29:1181–99

    Google Scholar 

  12. Whitehouse PJ, Price DL, Struble RG, et al (1982) Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 215:1237–1239

    Google Scholar 

  13. Sims NR, Bowen DM, Allen SJ, et al (1983) Presynaptic cholinesterase dysfunction in patients with dementia. J Neurochem 40:503–509

    Google Scholar 

  14. Rossor M, Mountjoy CQ (1986) Post-mortem neuro-chemical changes in Alzheimer's disease compared with normal aging. Can J Neurol Sci 13:499–502

    Google Scholar 

  15. Geula C, Mesulam MM (1994) Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease. In: Terry RD, Katzman R, Bick KL (eds) Alzheimer disease. Raven Press, New York, pp 263–291

    Google Scholar 

  16. Cutler NR, Sramek JJ, Seifert RD, Sawin SF (1993) The target population in phase I clinical trials of acetylcholinesterase inhibitors in dementia: the role of the “bridging study.” In: Corain B, Iqbal M, Nicolini M, Winblad B, Wisniewski H, Aztta P (eds) Alzheimer's disease: advances in clinical and basic research. Wiley, Sussex, pp 559–562

    Google Scholar 

  17. Cutler NR, Sramek JJ, Veroff AE (1994) Alzheimer's disease: optimizing drug development strategies. Wiley, Sussex

    Google Scholar 

  18. Puri SK, Hsu R, Ho I, Lassman HB (1989) Single dose safety, tolerance, and pharmacokinetics of HP 029 in young men: a potential Alzheimer's agent. J Clin Pharmacol 29:278–284

    Google Scholar 

  19. Puri SK, Hsu RS, Ho I, Lassman HB (1988) Single dose safety, tolerance and pharmacokinetics of HP 029 in healthy elderly men: a potential Alzheimer's agent. Curr Ther Res 44:766–780

    Google Scholar 

  20. Puri SK, Ho I, Lassman HB (1990) Multiple-dose pharmacokinetics, safety and tolerance of velnacrine (HP 029) in healthy elderly subjects: a potential therapeutic agent for Alzheimer's disease. J Clin Pharmacol 30:948–955

    Google Scholar 

  21. Cutler NR, Murphy MF, Nash RJ, Prior PL, DeLuna DM (1990) Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings. J Clin Pharmacol 30:556–561

    Google Scholar 

  22. Goldberg MR, Barchowsky A, McCrea J, et al (1991) Heptylphysostigmine (L-693,487): safety and cholinesterase inhibition in a placebo-controlled rising-dose healthy volunteer study. Presented at the Second International Springfield Symposium on Advances in Alzheimer Therapy, May 1991, Springfield

  23. Sramek JJ, Block GA, Reines SA, Sawin SF, Barchowsky A, Cutler NR (1994) A multiple-dose safety trial of eptastigmine in Alzheimer's disease with pharmacodynamic observations of red blood cell cholinesterase. Life Sciences 56:319–326

    Google Scholar 

  24. Davis R, Raby C, Callahan MJ, et al (1993) Subtype selective muscarinic agonists: potential therapeutic agents for Alzheimer's disease. Prog Brain Res 98:439–445

    Google Scholar 

  25. Sramek JJ, Sedman AJ, Reece PA, et al (1995) Safety and tolerability of CI-979 in patients with Alzheimer's disease. Life Sci 57:503–510

    Google Scholar 

  26. Sramek JJ, Hurley DJ, Wardle TS, et al (1995) The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease. J Clin Pharmacol (in press)

  27. Tollefson GD, Bodick NC, Shannon HC, Satterwhite JH, Sauerberg P (1994) Xanomeline: potent and specific M1 agonist in the treatment of Alzheimer's disease. Presented at the Annual Meeting of the American College of Neuropsychopharmacology, December 12–16, San Juan, Puerto Rico

  28. Storer BE (1989) Design and analysis of phase I clinical trials. Biometrics 45:925–937

    Google Scholar 

  29. Spilker B (1991) Guide to clinical trials. Raven Press, Ltd., New York, pp 96–97

    Google Scholar 

  30. Geller NL (1984) Design of phase I and II clinical trials in cancer: a statistician's view. Cancer Invest 2:483–491

    Google Scholar 

  31. Levy G, Ebling WF, Forrest A (1994) Concentration-or effect-controlled clinical trials with sparse data. Clin Pharm Ther 56:1–8

    Google Scholar 

  32. Cutler NR (1988) Utility of biologic markers in the evaluation and diagnosis of Alzheimer disease. Brain Dysfunction 1:12–31

    Google Scholar 

  33. Sramek JJ, Cutler NR, Hurley DJ, Seifert RD (1995) The utility of salivary amylase as an evaluation of M3 muscarinic agonist activity in Alzheimer's disease. Prog Neuro- Psychopharmacol Biol Psychiat 19:85–91

    Google Scholar 

  34. Dayan AD (1991) The limitations of animal studies: what can and cannot be predicted for man. Drug Info J 25:165–170

    Google Scholar 

  35. Fleming TR, DeMeets DL (1993) Monitoring of clinical trials: issues and recommendations. Controlled Clin Trials 14:183–197

    Google Scholar 

  36. Summers W, Majoski L, Marik G, Tachiki K, Kling A (1986) Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 315:1241–1245

    Google Scholar 

  37. Davis KL, Thal LJ, Gamzu ER, et al (1992) A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. New Engl J Med 327:1253–1259

    Google Scholar 

  38. Farlow M, Gracon SI, Hershey LA, et al. (1992) A controlled trial of tacrine in Alzheimer's disease. JAMA 268:2523–2529

    Google Scholar 

  39. Knapp MJ, Knopman DS, Solomon PR, et al. (1994) A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 271:985–991

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. California Clinical Trials, 8500 Wilshire Boulevard, 7th Floor, 90211, Beverly Hills, CA, USA

    N. R. Cutler & J. J. Sramek

Authors
  1. N. R. Cutler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. J. Sramek
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cutler, N.R., Sramek, J.J. Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study. Eur J Clin Pharmacol 48, 421–428 (1995). https://doi.org/10.1007/BF00194329

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00194329

Key words

Search

Navigation